Evidence map›Paper›PMID 38014049›Full record

ArticleResearch square2023

Application of machine learning models to identify serological predictors of COVID-19 severity and outcomes.

Sabra Klein, Santosh Dhakal, Anna Yin, Marta Escarra-Senmarti, Zoe Demko, Nora Pisanic, Trevor Johnston, Maria Trejo-Zambrano, Kate Kruczynski, John Lee and 18 more

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 1 institution in 1 country.

Sabra KleinJohns Hopkins Bloomberg School of Public Health.ORCID https://orcid.org/0000-0002-0730-5224
Santosh DhakalJohns Hopkins Bloomberg School of Public Health.
Anna YinJohns Hopkins Bloomberg School of Public Health.
Marta Escarra-SenmartiJohns Hopkins School of Medicine.ORCID https://orcid.org/0000-0002-3134-5568
Zoe DemkoJohns Hopkins School of Medicine.
Nora PisanicJohns Hopkins Bloomberg School of Public Health.
Trevor JohnstonJohns Hopkins Bloomberg School of Public Health.ORCID https://orcid.org/0000-0002-8662-541X
Maria Trejo-ZambranoJohns Hopkins School of Medicine.
Kate KruczynskiJohns Hopkins Bloomberg School of Public Health.
John LeeJohns Hopkins Bloomberg School of Public Health.
Justin HardickThe Johns Hopkins University.
Patrick SheaJohns Hopkins Bloomberg School of Public Health.
Janna ShapiroJohns Hopkins Bloomberg School of Public Health.
Han-Sol ParkJohns Hopkins Bloomberg School of Public Health.
Maclaine ParishJohns Hopkins Bloomberg School of Public Health.
Christopher CaputoJohns Hopkins Bloomberg School of Public Health, Baltimore.
Abhinaya GanesanJohns Hopkins Bloomberg School of Public Health.
Sarika MullapudiJohns Hopkins School of Medicine.ORCID https://orcid.org/0000-0002-9257-2959
Stephen GouldJohns Hopkins University School of Medicine.
Michael BetenbaughJohns Hopkins University.
Andrew PekoszJohns Hopkins Bloomberg School of Public Health.ORCID https://orcid.org/0000-0003-3248-1761
Christopher D HeaneyJohns Hopkins.ORCID https://orcid.org/0000-0003-3211-8495
Annukka AntarJohns Hopkins School of Medicine.
Yukari ManabeDivision of Infectious Diseases, Department of Medicine, The Johns Hopkins School of Medicine.ORCID https://orcid.org/0000-0001-8619-5598
Andrea CoxJohns Hopkins University.ORCID https://orcid.org/0000-0002-9331-2462
Andrew KarabaJohns Hopkins University.ORCID https://orcid.org/0000-0003-2785-317X
Felipe AndradeJohns Hopkins University.ORCID https://orcid.org/0000-0003-3415-0704
Scott ZegerJohns Hopkins University.
Johns Hopkins University · US

Funding

Virology Resource CoreU54CA260492 · NCI · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L, KLEIN, SABRA L. · 2020 to 2024
$10.4M
NCI NIH HHS U54 CA260492
6 · The paper itself

Abstract

Critically ill people with COVID-19 have greater antibody titers than those with mild to moderate illness, but their association with recovery or death from COVID-19 has not been characterized. In 178 COVID-19 patients, 73 non-hospitalized and 105 hospitalized patients, mucosal swabs and plasma samples were collected at hospital enrollment and up to 3 months post-enrollment (MPE) to measure virus RNA, cytokines/chemokines, binding antibodies, ACE2 binding inhibition, and Fc effector antibody responses against SARS-CoV-2. The association of demographic variables and >20 serological antibody measures with intubation or death due to COVID-19 was determined using machine learning algorithms. Predictive models revealed that IgG binding and ACE2 binding inhibition responses at 1 MPE were positively and C1q complement activity at enrollment was negatively associated with an increased probability of intubation or death from COVID-19 within 3 MPE. Serological antibody measures were more predictive than demographic variables of intubation or death among COVID-19 patients.

Indexed as

automated intelligenceCOVID-19 deathCOVID-19 hospitalizationIgG isotypesneutralizing antibodynon-neutralizing antibodyrandom forest model

Identifiers

PMID38014049
PMCPMC10680931
OpenAlexW4388639384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.